Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2002

01-01-2002 | Original Article

Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo

Authors: Tsugitaka Natsume, Yasuhiro Koh, Motohiro Kobayashi, Hisao Fukumoto, Fumiyuki Takahashi, Takashi Nakamura, Yuichiro Ohe, Nagahiro Saijo, Kazuto Nishio

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002

Login to get access
Metadata
Title
Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo
Authors
Tsugitaka Natsume
Yasuhiro Koh
Motohiro Kobayashi
Hisao Fukumoto
Fumiyuki Takahashi
Takashi Nakamura
Yuichiro Ohe
Nagahiro Saijo
Kazuto Nishio
Publication date
01-01-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-001-0388-0

Other articles of this Issue 1/2002

Cancer Chemotherapy and Pharmacology 1/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine